Royalty Pharma plc Equity Securities, FV-NI, Unrealized Gain (Loss)
Royalty Pharma plc (RPRX) reported Equity Securities, FV-NI, Unrealized Gain (Loss) of $69.16 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss · last filed 2026-08-05
- Royalty Pharma plc equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-06-30 was $69.16M.
- Royalty Pharma plc equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2026-03-31 was -$20.17M.
- Royalty Pharma plc equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-12-31 was $35.72M.
- Royalty Pharma plc equity securities, fv-ni, unrealized gain (loss) for the quarter ending 2025-09-30 was $18.86M, a 62.90% decline year-over-year.
- Royalty Pharma plc equity securities, fv-ni, unrealized gain (loss) for fiscal 2025 was -$21.85M, a 155.25% decline from fiscal 2024.
- Royalty Pharma plc equity securities, fv-ni, unrealized gain (loss) for fiscal 2024 was $39.55M, a 54.61% decline from fiscal 2023.
- Royalty Pharma plc equity securities, fv-ni, unrealized gain (loss) for fiscal 2023 was $87.14M.
- Royalty Pharma plc equity securities, fv-ni, unrealized gain (loss) for fiscal 2022 was -$33.44M.
| Period end | Equity Securities, FV-NI, Unrealized Gain (Loss) 3 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 6 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 9 month | Equity Securities, FV-NI, Unrealized Gain (Loss) 12 month |
|---|---|---|---|---|
| 2026-06-30 | $69.16M 10-Q · filed 2026-08-05 | $48.99M 10-Q · filed 2026-08-05 | $84.71M derived: sum of 3 quarters · filed 2026-08-05 | $103.57M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | -$20.17M 10-Q · filed 2026-05-06 | $15.55M derived: sum of 2 quarters · filed 2026-05-06 | $34.41M derived: sum of 3 quarters · filed 2026-05-06 | $3.86M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $35.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $54.58M derived: sum of 2 quarters · filed 2026-02-11 | $24.03M derived: sum of 3 quarters · filed 2026-08-05 | -$21.85M 10-K · filed 2026-02-11 |
| 2025-09-30 | $18.86M 10-Q · filed 2025-11-05 | -$11.69M derived: sum of 2 quarters · filed 2026-08-05 | -$57.57M 10-Q · filed 2025-11-05 | -$99.47M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | -$30.55M 10-Q · filed 2026-08-05 | -$76.43M 10-Q · filed 2026-08-05 | -$118.34M derived: sum of 3 quarters · filed 2026-08-05 | -$67.49M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | -$45.88M 10-Q · filed 2026-05-06 | -$87.78M derived: sum of 2 quarters · filed 2026-05-06 | -$36.94M derived: sum of 3 quarters · filed 2026-05-06 | -$84.06M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | -$41.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $8.94M derived: sum of 2 quarters · filed 2026-02-11 | -$38.18M derived: sum of 3 quarters · filed 2026-02-11 | $39.55M 10-K · filed 2026-02-11 |
| 2024-09-30 | $50.85M 10-Q · filed 2025-11-05 | $3.73M derived: sum of 2 quarters · filed 2025-11-05 | $81.45M 10-Q · filed 2025-11-05 | $136.60M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-06-30 | -$47.12M 10-Q · filed 2025-08-06 | $30.61M 10-Q · filed 2025-08-06 | $85.75M derived: sum of 3 quarters · filed 2026-02-11 | $87.29M derived: sum of 4 quarters · filed 2026-02-11 |
| 2024-03-31 | $77.73M 10-Q · filed 2025-05-08 | $132.88M derived: sum of 2 quarters · filed 2026-02-11 | $134.42M derived: sum of 3 quarters · filed 2026-02-11 | $175.69M derived: sum of 4 quarters · filed 2026-02-11 |
| 2023-12-31 | $55.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-11 | $56.69M derived: sum of 2 quarters · filed 2026-02-11 | $97.96M derived: sum of 3 quarters · filed 2026-02-11 | $87.14M 10-K · filed 2026-02-11 |
| 2023-09-30 | $1.54M 10-Q · filed 2024-11-06 | $42.81M derived: sum of 2 quarters · filed 2024-11-06 | $31.99M 10-Q · filed 2024-11-06 | $21.52M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-06-30 | $41.27M 10-Q · filed 2024-08-08 | $30.45M 10-Q · filed 2024-08-08 | $19.98M derived: sum of 3 quarters · filed 2025-02-12 | $25.15M derived: sum of 4 quarters · filed 2025-02-12 |
| 2023-03-31 | -$10.82M 10-Q · filed 2024-05-09 | -$21.29M derived: sum of 2 quarters · filed 2025-02-12 | -$16.12M derived: sum of 3 quarters · filed 2025-02-12 | -$8.10M derived: sum of 4 quarters · filed 2025-02-12 |
| 2022-12-31 | -$10.47M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$5.30M derived: sum of 2 quarters · filed 2025-02-12 | $2.72M derived: sum of 3 quarters · filed 2025-02-12 | -$33.44M 10-K · filed 2025-02-12 |
| 2022-09-30 | $5.17M 10-Q · filed 2023-11-08 | $13.19M derived: sum of 2 quarters · filed 2023-11-08 | -$22.97M 10-Q · filed 2023-11-08 | -$53.06M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-06-30 | $8.02M 10-Q · filed 2023-08-08 | -$28.14M 10-Q · filed 2023-08-08 | -$58.22M derived: sum of 3 quarters · filed 2024-02-15 | -$77.51M derived: sum of 4 quarters · filed 2024-02-15 |
| 2022-03-31 | -$36.16M 10-Q · filed 2023-05-09 | -$66.25M derived: sum of 2 quarters · filed 2024-02-15 | -$85.54M derived: sum of 3 quarters · filed 2024-02-15 | -$30.04M derived: sum of 4 quarters · filed 2024-02-15 |
| 2021-12-31 | -$30.09M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-15 | -$49.38M derived: sum of 2 quarters · filed 2024-02-15 | $6.12M derived: sum of 3 quarters · filed 2024-02-15 | -$48.07M 10-K · filed 2024-02-15 |
| 2021-09-30 | -$19.29M 10-Q · filed 2022-11-08 | $36.21M derived: sum of 2 quarters · filed 2022-11-08 | -$17.98M 10-Q · filed 2022-11-08 | $28.14M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-06-30 | $55.49M 10-Q · filed 2022-08-04 | $1.31M 10-Q · filed 2022-08-04 | $47.43M derived: sum of 3 quarters · filed 2023-02-15 | $207.65M derived: sum of 4 quarters · filed 2023-02-15 |
| 2021-03-31 | -$54.19M 10-Q · filed 2022-05-05 | -$8.07M derived: sum of 2 quarters · filed 2023-02-15 | $152.16M derived: sum of 3 quarters · filed 2023-02-15 | $346.05M derived: sum of 4 quarters · filed 2023-02-15 |
| 2020-12-31 | $46.12M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-15 | $206.34M derived: sum of 2 quarters · filed 2023-02-15 | $400.24M derived: sum of 3 quarters · filed 2023-02-15 | $247.07M 10-K · filed 2023-02-15 |
| 2020-09-30 | $160.23M 10-Q · filed 2021-11-10 | $354.12M derived: sum of 2 quarters · filed 2021-11-10 | $200.96M 10-Q · filed 2021-11-10 | $346.68M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-06-30 | $193.90M 10-Q · filed 2021-08-11 | $40.73M 10-Q · filed 2021-08-11 | $186.46M derived: sum of 3 quarters · filed 2022-02-15 | $179.53M derived: sum of 4 quarters · filed 2022-02-15 |
| 2020-03-31 | -$153.17M 10-Q · filed 2021-05-11 | -$7.44M derived: sum of 2 quarters · filed 2022-02-15 | -$14.36M derived: sum of 3 quarters · filed 2022-02-15 | -$51.16M derived: sum of 4 quarters · filed 2022-02-15 |
| 2019-12-31 | $145.73M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-15 | $138.81M derived: sum of 2 quarters · filed 2022-02-15 | $102.00M derived: sum of 3 quarters · filed 2022-02-15 | $155.75M 10-K · filed 2022-02-15 |
| 2019-09-30 | -$6.92M 10-Q · filed 2020-11-12 | -$43.72M derived: sum of 2 quarters · filed 2020-11-12 | $10.02M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | -$36.80M 10-Q · filed 2020-08-12 | $16.94M 10-Q · filed 2020-08-12 | ||
| 2018-12-31 | -$13.94M 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |